Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ERGO (fights fat, diabetes II, and Heart disease) -- Ignore unavailable to you. Want to Upgrade?

To: mfr who wrote (87)	6/8/1998 11:06:00 AM
From: Rudy Saucillo	Respond to of 110

mfr, Today's BioCentury mentions that ERGO met with the FDA and is putting together a clinical plan to address questions raised by the advisory committee. Donna LaVoie (ERGO spokesperson) stated the plan "could include additional studies, and it could include presenting the data in a different manner, or it could be a combination of both." Given the serious issues raised at the ERGO panel, it's obvious that the FDA and advisory committee are not looking for "presenting the data in a different manner." Personnally, I'd be very surprised if an additional trial is not required. Rudy